Table 1. Baseline characteristics of... | American Society of Hematology

Table 1.

Baseline characteristics of BR-treated cohort compared with an historical RCVP-treated cohort

Characteristic	BR (N = 296), n	%	RCVP (N = 347), n	%	P
Age >60 y	153	52	189	54	.5
Male	163	55	195	56	.8
Ann Arbor stage III/IV	245	83	305	88	.02
Elevated LDH	67	23	73	23	.9
Bone marrow involved	136	46	178	51	.2
B-symptoms	68	23	78	22	.4
Low hemoglobin <120 g/L	47	16	61	19	.3
FLIPI (missing)	6	2	52	15
Low (0-1)	74	25	43	12	.002
Intermediate (2)	106	36	107	31
High (3-5)	110	37	145	42
FL grade 1/2	254	87	295	85	.5
FL grade 3A	39	13	52	15	.5
Initial observation	34	11	87	25	<.001
Maintenance rituximab	243	84	284	82	.4

Characteristic	BR (N = 296), n	%	RCVP (N = 347), n	%	P
Age >60 y	153	52	189	54	.5
Male	163	55	195	56	.8
Ann Arbor stage III/IV	245	83	305	88	.02
Elevated LDH	67	23	73	23	.9
Bone marrow involved	136	46	178	51	.2
B-symptoms	68	23	78	22	.4
Low hemoglobin <120 g/L	47	16	61	19	.3
FLIPI (missing)	6	2	52	15
Low (0-1)	74	25	43	12	.002
Intermediate (2)	106	36	107	31
High (3-5)	110	37	145	42
FL grade 1/2	254	87	295	85	.5
FL grade 3A	39	13	52	15	.5
Initial observation	34	11	87	25	<.001
Maintenance rituximab	243	84	284	82	.4